Drug shortages
HHS proposes policies to prevent drug shortages. Find out how AHA is collaborating with the private sector to mitigate supply chain vulnerabilities.
AHA, others urge Senate HELP Committee to advance MEDS Act (S.2723).
The Food and Drug Administration today released a proposed rule that would allow states and other non-federal government entities to establish programs to import certain FDA-approved prescription drug and biological products from Canada.
Drug shortages threaten the quality of patient care, narrow treatment options and often result in the use of potentially less effective alternative medications, hospital and health system leaders said at a briefing today on Capitol Hill.
The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists and Institute for Safe Medication Practices today voiced strong support for the Mitigating Emergency Drug Shortages Act.
The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists and Institute for Safe Medication Practices voiced strong support for the Mitigating Emergency Drug Shortages Act (S.2723), which includes provisions recommended by a…
The Food and Drug Administration approved a record high 1,171 generic drugs in fiscal year 2019, the agency said today.
The AHA and six other organizations today submitted comments to the Drug Enforcement Administration on its proposed rule regarding controlled substances quotas.
The AHA and six other organizations comments to the Drug Enforcement Administration on its proposed rule regarding controlled substances quotas.
In what is being hailed as a model for provider-led innovation, Civica Rx, the startup formed last year by a group of health systems to combat rising drug prices and shortages of drugs long on the market, recently made its first delivery of generic medications to a hospital.
The AHA appreciates the opportunity to comment on the Drug Enforcement Administration’s proposed notice on aggregate production quotas for schedule I and II controlled substances.